Evidence map›Paper›PMID 37846469›Full record

Trial reportCancer research and treatment2024

A Single-Arm Phase II Study of Nab-Paclitaxel Plus Gemcitabine and Cisplatin for Locally Advanced or Metastatic Biliary Tract Cancer.

Ting Liu, Qing Li, Zhen Lin, Chunhua Liu, Wei Pu, Shasha Zeng, Jun Lai, Xuebin Cai, Lisha Zhang, Shuyang Wang and 4 more

Open access · diamondAbstract readClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Cancer research and treatment, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
1.6field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 5 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 1 country.

Ting LiuDepartment of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Sichuan, China.
Qing LiDepartment of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Sichuan, China.
Zhen LinDepartment of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Sichuan, China.
Chunhua LiuDepartment of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Sichuan, China.
Wei PuDepartment of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Sichuan, China.
Shasha ZengThoracic Oncology Ward, Cancer Center, West China Hospital, Sichuan University, Sichuan, China.
Jun LaiDepartment of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Sichuan, China.
Xuebin CaiDepartment of Abdominal Oncology, Cancer Center, West China Hospital, Sichuan University, Sichuan, China.
Lisha ZhangDepartment of Abdominal Oncology, Cancer Center, West China Hospital, Sichuan University, Sichuan, China.
Shuyang WangDepartment of Abdominal Oncology, Cancer Center, West China Hospital, Sichuan University, Sichuan, China.
Miao ChenDepartment of Abdominal Oncology, Cancer Center, West China Hospital, Sichuan University, Sichuan, China.
Wei CaoDepartment of Abdominal Oncology, Cancer Center, West China Hospital, Sichuan University, Sichuan, China.
Hongfeng GouDepartment of Gastric Cancer Center, Division of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, Sichuan, China.
Qing ZhuDepartment of Abdominal Oncology, Cancer Center, West China Hospital, Sichuan University, Sichuan, China.
Sichuan University · CNSichuan Cancer Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposePatients with advanced biliary tract cancer (BTC) have a poor survival. We aim to evaluate the efficacy and safety of nab-paclitaxel plus gemcitabine and cisplatin regimen in Chinese advanced BTC patients. MATERIALS AND

methodsEligible patients with locally advanced or metastatic BTC administrated intravenous 100 mg/m2 nab-paclitaxel, 800 mg/m2 gemcitabine, and 25 mg/m2 cisplatin every 3 weeks. The primary endpoint was progression-free survival (PFS). The secondary endpoints included overall survival (OS) and adverse events, while exploratory endpoint was the association of biomarkers with efficacy.

resultsAfter the median follow-up of 25.0 months, the median PFS and OS of 34 enrolled patients were 7.1 months (95% confidence interval [CI], 5.4 to 13.7) and 16.4 months (95% CI, 10.9 to 23.6), respectively. The most common treatment-related adverse events at ≥ 3 grade were neutropenia (26.5%) and leukopenia (26.5%). Survival analyses demonstrated that carcinoembryonic antigen (CEA) levels could monitor patients' survival outcomes. A significant increase in the number of infiltrating CD4+ cells (p=0.008) and a decrease in programmed death-1-positive (PD-1+) cells (p=0.032) were observed in the response patients.

conclusionIn advanced BTC patients, nab-paclitaxel plus gemcitabine and cisplatin regimen showed therapeutic potential. Potential prognostic factors of CEA levels, number of CD4+ cells and PD-1+ cells may help us maximize the efficacy benefit.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsBile Duct NeoplasmsAlbuminsCarcinoembryonic AntigenCisplatinGemcitabineHumansPaclitaxelProgrammed Cell Death 1 Receptor130-nm albumin-bound paclitaxelAlbuminsCarcinoembryonic AntigenCisplatinGemcitabinePaclitaxelProgrammed Cell Death 1 ReceptorBiliary tract neoplasmsCisplatinGemcitabineNab-paclitaxelTumor microenvironment

Identifiers

PMID37846469
PMCPMC11016659
OpenAlexW4387542261

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.